Who
Sanam Pangali
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Alumis; CLO & Head of People, Acelyrin.
In numbers
- Trades disclosed
- 16
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $354K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 May 2024
- Last trade
- 2 Nov 2026
- Last filed
- 4 Nov 2026
Companies traded
Activity over time
1 Jul – 1 Nov
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Nov 2026filed 4 Nov 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $2,165332 at $6.52 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $36K1,364 at $26.37 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $36K1,364 at $26.37 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Code M | $25K5,000 at $5.06 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $140K5,000 at $28.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Code M | $25K5,000 at $5.06 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $140K5,000 at $28.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,200 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,200 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | ALMS AlumisBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Jul 2025filed 14 Jul 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | Acelyrinoption or derivative | SEC FORM 4 Code A | —328,860 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | Acelyrin | SEC FORM 4 Code F | $4,117921 at $4.47 | filing |
News
Critical Review: Connect Biopharma (NASDAQ:CNTB) & Alumis (NASDAQ:ALMS)ALMS · themarketsdaily.com · 3 Nov 2026
0 headlines in the last 90 days name Sanam Pangali; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.